BPC-157
Body Protection Compound-157
BPC-157 is a 15-amino-acid partial sequence derived from human gastric juice proteins. It has attracted significant preclinical research interest for its effects on musculoskeletal tissue repair, gastrointestinal healing, and nitric oxide pathway modulation.
Mechanism of Action
BPC-157 exerts its primary effects through upregulation of the nitric oxide (NO) signalling pathway. By promoting NO synthase activity, it drives vasodilation and angiogenesis at injury sites, accelerating the delivery of repair-critical growth factors.
Research also suggests BPC-157 interacts with the VEGFR2 receptor (vascular endothelial growth factor receptor), promoting new blood vessel formation in damaged connective tissue. This mechanism is thought to underpin its observed effects on tendon, ligament, and muscle repair in animal models.
Additionally, BPC-157 has been shown to modulate dopaminergic and serotonergic signalling in the central nervous system in rodent studies, which may partially explain reported effects on stress tolerance and gut-brain axis function.
Research Evidence
The majority of BPC-157 research is preclinical (animal and in vitro). No large-scale randomised controlled trials in humans have been published as of 2026. The FDA's 2024 assessment noted insufficient human safety and efficacy data to support therapeutic use, removing it from permissible compounding lists. However, the breadth of animal model evidence across multiple organ systems has sustained research interest.
BPC-157 Accelerates Tendon Healing in Rat Achilles Tendon Transection Model
Subcutaneous BPC-157 significantly accelerated gross and histological healing of complete Achilles tendon transections, with improved tendon organisation versus controls at both 1- and 2-week timepoints.
Gastric Pentadecapeptide BPC-157 in Inflammatory Bowel Disease Models
Oral and parenteral BPC-157 reduced mucosal inflammation and promoted epithelial regeneration in both TNBS- and cysteamine-induced ulceration models, suggesting GI protective properties independent of route.
BPC-157 and NO-System Interactions in Wound Healing
Comprehensive review confirming NO pathway centrality in BPC-157 wound healing effects; noted synergistic action with L-arginine and antagonism with NOS inhibitors, confirming mechanism specificity.
Typical Research Protocol
No established human therapeutic dose exists. Ranges cited are derived from animal-to-human dose extrapolations used in research contexts. Oral BPC-157 has been studied for GI applications; stability in GI tract is debated.
Safety Profile
Reported Side Effects
- Injection site redness or bruising
- Mild nausea (oral form)
- Transient dizziness
- Warmth at injection site
Contraindications
- Active malignancy (theoretical growth stimulation concern)
- Pregnancy (no safety data)
- Concurrent anticoagulant therapy (caution)
- Known peptide hypersensitivity
Published Research
222 indexed PubMed papers reference BPC-157. The 20 most recent are listed below.
- BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence.
-
Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs.
PMID 42757290 Open on PubMed →
-
Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards.
PMID 42752426 Open on PubMed →
- Efficient Expression of Small Molecule Bioactive Peptides in Bacillus licheniformis.
- Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine.
- Fabrication and characterization of biocompatible BPC-157 based chitosan hydrogel.
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.
- Stable pentadecapeptide therapy counteracts gentamicin-induced nephrotoxicity via nitric oxide-system modulation: evidence from a triple nitric oxide-agent approach in rats.
- Effects of Supplementation in Masters Athletes and Older Adults: A Narrative Review.
- Unilateral Adrenalectomy, and the Stable Pentadecapeptide BPC 157 as Therapy in Rats-A Cytoprotection Approach.
- Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.
- BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.
-
Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation.
PMID 42222211 Open on PubMed →
- Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury.
- BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers.
- Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
- Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
- Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery.
- Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
Common Research Stacks
Frequently Asked Questions
Is BPC-157 legal to purchase?
In most countries, BPC-157 is not approved for human therapeutic use. In the US, it was removed from permissible compounding lists by the FDA in 2024. It remains available as a research chemical from laboratory suppliers in many jurisdictions. Always verify the current legal status in your country.
Does BPC-157 work orally?
Oral BPC-157 has been studied specifically for gastrointestinal conditions, where local gut exposure is the target. Systemic bioavailability via oral administration is debated — some researchers argue the peptide is degraded in the GI tract before absorption, while others cite evidence of partial absorption. Subcutaneous injection is generally considered the more reliable route for systemic effects.
How long does BPC-157 take to show effects?
In animal models, observable tissue healing improvements were noted within 1–2 weeks. In research contexts, protocols typically run 4–12 weeks. Individual response variability and the nature of the injury being studied significantly affect timelines.
Can BPC-157 be used for gastrointestinal conditions?
Yes — GI protection is one of BPC-157's most consistent findings. It heals gastric ulcers, reduces colitis markers, and protects the gut lining across multiple animal models. Oral administration is specifically studied for GI applications since direct mucosal contact may be the active mechanism rather than systemic absorption.
What is the difference between BPC-157 and Pentadeca Arginate (PDA)?
Pentadeca Arginate (PDA) is a modified form of BPC-157 with an arginine substitution that improves stability and does not require refrigeration. PDA also has enhanced nitric oxide pathway activity. Both share the 15-amino-acid backbone and similar mechanisms; PDA is sometimes chosen when storage or shipping conditions make refrigeration impractical.
Should BPC-157 be injected near the injury site?
Local injection near the injury is common practice — BPC-157's angiogenic and NO pathway effects are concentrated in the area surrounding the injection site, which provides the most targeted repair signal. For systemic or GI applications, abdominal SC injection is practical. There is no definitive human data proving local superiority over remote injection.
Key Research References
- Sikiric P et al. (2010). Stable gastric pentadecapeptide BPC-157: novel therapy in gastrointestinal tract. Curr Pharm Des.
- Gwyer D et al. (2019). Gastric pentadecapeptide body protection compound BPC-157. Curr Pharm Des.
- Chang CH et al. (2011). Bone healing effects of BPC-157. J Orthop Res.
Explore more Recovery research compounds
Browse Recovery →